
Full profile: /officials/B001300
Source: Congress.gov · FEC
Members who have signed on to support this bill since introduction. Source: Congress.gov.
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2026-06-24
Source: Congress.gov
Currently in
Medicare patients and drug manufacturers would gain a formal review process to challenge decisions by Medicare that deny coverage for certain medications nationwide. Currently, when Medicare decides not to cover a drug, there is limited opportunity to appeal that decision; this change would create a structured way to request reconsideration and present new evidence. The review process would apply specifically to these national coverage denials, giving patients and companies a clearer path to contest decisions they believe are unfair.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Bills by the same sponsor or covering overlapping subjects.